Download PDF
Horm Metab Res 2023; 55(01): 75-84
DOI: 10.1055/a-1970-3388
Original Article: Endocrine Research

Dapagliflozin Presented Nonalcoholic Fatty Liver Through Metabolite Extraction and AMPK/NLRP3 Signaling Pathway

Deng Lin
1   Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
,
Yuling Song
1   Department of Endocrinology, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

In recent years, the incidence rate of nonalcoholic fatty liver disease (NAFLD) has been increasing year by year. The experiments conducted on rat elucidated the effect and underlying mechanism of dapagliflozin in NAFLD. Sprague Dawley rats were fed with HFD (Fat accounts for 52%, carbohydrate 34% and protein 14%) for 12 weeks as NAFLD model. Dapagliflozin presented NAFLD in rat model. Dapagliflozin reduced oxidative stress and inflammation in rat model of NAFLD. Dapagliflozin reduced oxidative stress and inflammation in vitro model of NAFLD. Dapagliflozin in a model of NAFLD metabolized into histamine H1 receptor, caffeine metabolism, mannose type O-glycan biosynthesis, choline metabolism in cancer, tryptophan metabolism, and glycerophospholipid metabolism. Dapagliflozin induced AMPK/NLRP3 signaling pathway. The regulation of AMPK/NLRP3 signaling pathway affected the effects of dapagliflozin on nonalcoholic fatty liver. In summary, dapagliflozin plays a preventative role in NAFLD through metabolite extraction, the inhibition of oxidative stress, and inflammation by AMPK/NLRP3 signaling pathway. Dapagliflozin may be a potential therapeutic agent for oxidative stress and inflammation in model of NAFLD.

Key words

dapagliflozin - nonalcoholic fatty liver - metabolite extraction - AMPK - NLRP3


Publication History

Received: 23 June 2022

Accepted after revision: 14 October 2022

Article published online:
09 December 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Chrysavgis L, Giannakodimos I, Diamantopoulou P. et al. Non-alcoholic fatty liver disease and hepatocellular carcinoma: clinical challenges of an intriguing link. World J Gastroenterol 2022; 28: 310-31
    CrossrefPubMedGoogle Scholar
  • 2 Huang Y, Gan Q, Lai R. et al. Application of fatty liver inhibition of progression algorithm and steatosis, activity, and fibrosis score to assess the impact of non-alcoholic fatty liver on untreated chronic hepatitis B patients. Front Cell Infect Microbiol 2021; 11: 733348
    CrossrefPubMedGoogle Scholar
  • 3 Liu L, Fu Q, Li T. et al. Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. PLoS One 2022; 17: e0262855
    CrossrefPubMedGoogle Scholar
  • 4 Cunha GM, Delgado T, Middleton MS. et al. Automated CNN-based analysis versus manual analysis for MR elastography in nonalcoholic fatty liver disease: inter-method agreement and fibrosis stage discriminative performance. AJR Am J Roentgenol 2022; 219: 224-232
    CrossrefPubMedGoogle Scholar
  • 5 Chen ZY, Sun YT, Wang ZM. et al. Rab2A regulates the progression of nonalcoholic fatty liver disease downstream of AMPK-TBC1D1 axis by stabilizing PPARγ. PLoS Biol 2022; 20: e3001522
    CrossrefPubMedGoogle Scholar
  • 6 Fouqueray P, Bolze S, Dubourg J. et al. Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: a phase 1b study. Cell Rep Med 2021; 2: 100474
    CrossrefPubMedGoogle Scholar
  • 7 Zhou F, Ding M, Gu Y. et al. Aurantio-obtusin attenuates non-alcoholic fatty liver disease through AMPK-mediated autophagy and fatty acid oxidation pathways. Front Pharmacol 2021; 12: 826628
    CrossrefPubMedGoogle Scholar
  • 8 Chen YC, Chen RJ, Peng SY. et al. Therapeutic targeting of nonalcoholic fatty liver disease by downregulating SREBP-1C expression via AMPK-KLF10 axis. Front Mol Biosci 2021; 8: 751938
    CrossrefPubMedGoogle Scholar
  • 9 Jiang X, Gu Y, Huang Y. et al. CBD alleviates liver injuries in alcoholics with high-fat high-cholesterol diet through regulating NLRP3 inflammasome-pyroptosis pathway. Front Pharmacol 2021; 12: 724747
    CrossrefPubMedGoogle Scholar
  • 10 Pu Z, Liu Y, Li C. et al. Using network pharmacology for systematic understanding of geniposide in ameliorating inflammatory responses in colitis through suppression of NLRP3 inflammasome in macrophage by AMPK/Sirt1 dependent signaling. Am J Chin Med 2020; 48: 1693-1713
    CrossrefPubMedGoogle Scholar
  • 11 Oh S, Son M, Byun KA. et al. Attenuating effects of dieckol on high-fat diet-induced nonalcoholic fatty liver disease by decreasing the NLRP3 inflammasome and pyroptosis. Mar Drugs 2021; 19: 318 DOI: 10.3390/md19060318.
    CrossrefPubMedGoogle Scholar
  • 12 Pan MX, Zheng CY, Deng YJ. et al. Hepatic protective effects of Shenling Baizhu powder, a herbal compound, against inflammatory damage via TLR4/NLRP3 signalling pathway in rats with nonalcoholic fatty liver disease. J Integr Med 2021; 19: 428-438
    CrossrefPubMedGoogle Scholar
  • 13 El-Safty H, Ismail A, Mohsen R. et al. Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt/β-Catenin and CREB pathway. Brain Res Bull 2022; 181: 109-120
    CrossrefPubMedGoogle Scholar
  • 14 El Medany AMH, Hammadi SHM, Khalifa HM. et al. The vascular impact of dapagliflozin, liraglutide and atorvastatin alone or in combinations in type 2 diabetic rat model. Fundam Clin Pharmacol 2022; 36: 731-741
    CrossrefPubMedGoogle Scholar
  • 15 Liu L, Luo H, Liang Y. et al. Dapagliflozin ameliorates STZ-induced cardiac hypertrophy in type 2 diabetic rats by inhibiting the calpain-1 expression and nuclear transfer of NF-κB. Comput Math Methods Med 2022; 3293054
    PubMedGoogle Scholar
  • 16 Ding X, Jian T, Li J. et al. Chicoric acid ameliorates nonalcoholic fatty liver disease via the AMPK/Nrf2/NFκB signaling pathway and restores gut microbiota in high-fat-diet-fed mice. Oxid Med Cell Longev 2020; 9734560
    PubMedGoogle Scholar
  • 17 Zhang W, Wang W, Xu M. et al. GPR43 regulation of mitochondrial damage to alleviate inflammatory reaction in sepsis. Aging (Albany NY) 2021; 13: 22588-22610
    CrossrefPubMedGoogle Scholar
  • 18 Pu Z, Zhang W, Wang M. et al. Schisandrin B attenuates colitis-associated colorectal cancer through SIRT1 linked SMURF2 signaling. Am J Chin Med 2021; 49: 1773-1789
    CrossrefPubMedGoogle Scholar
  • 19 Tsujimoto T, Arai R, Yoshitomi T. et al. UHPLC/MS and NMR-based metabolomic analysis of dried water extract of citrus-type crude drugs. Chem Pharm Bull (Tokyo) 2021; 69: 741-746
    CrossrefPubMedGoogle Scholar
  • 20 Liu X, Zhang Y, Ma C. et al. Alternate-day fasting alleviates high fat diet induced non-alcoholic fatty liver disease through controlling PPARα/Fgf21 signaling. Mol Biol Rep 2022; 49: 3113-3122
    CrossrefPubMedGoogle Scholar
  • 21 Parameswaran M, Hasan HA, Sadeque J. et al. Factors that predict the progression of non-alcoholic fatty liver disease (NAFLD). Cureus 2021; 13: e20776
    PubMedGoogle Scholar
  • 22 Liu Q, Liu C, Hu F. et al. Non-alcoholic fatty liver disease and longitudinal cognitive changes in middle-aged and elderly adults. Front Med (Lausanne) 2021; 8: 738835
    CrossrefPubMedGoogle Scholar
  • 23 Zambon Azevedo V, Silaghi CA, Maurel T. et al. Impact of sarcopenia on the severity of the liver damage in patients with non-alcoholic fatty liver disease. Front Nutr 2021; 8: 774030
    CrossrefPubMedGoogle Scholar
  • 24 Hazem RM, Ibrahim AZ, Ali DA. et al. Dapagliflozin improves steatohepatitis in diabetic rats via inhibition of oxidative stress and inflammation. Int Immunopharmacol 2022; 104: 108503
    CrossrefPubMedGoogle Scholar
  • 25 Clinton CM, Bain JR, Muehlbauer MJ. et al. Non-targeted urinary metabolomics in pregnancy and associations with fetal growth restriction. Sci Rep 2020; 10: 5307
    CrossrefPubMedGoogle Scholar
  • 26 Cloteau C, Dervilly G, Kaabia Z. et al. From a non-targeted metabolomics approach to a targeted biomarkers strategy to highlight testosterone abuse in equine. Illustration of a methodological transfer between platforms and laboratories. Drug Test Anal 2022; 14: 864-878
    CrossrefPubMedGoogle Scholar
  • 27 Xue W, Zhang H, Wang M. et al. Metabolomics-based non-targeted screening analysis of 34 PPCPs in bovine and piscine muscles. Anal Methods 2022; 14: 233-240
    CrossrefPubMedGoogle Scholar
  • 28 Kappel BA, Moellmann J, Thiele K. et al. Human and mouse non-targeted metabolomics identify 1,5-anhydroglucitol as SGLT2-dependent glycemic marker. Clin Transl Med 2021; 11: e470
    CrossrefPubMedGoogle Scholar
  • 29 Li J, Cheng B, Xie H. et al. Bladder cancer biomarker screening based on non-targeted urine metabolomics. Int Urol Nephrol 2022; 54: 23-29
    CrossrefPubMedGoogle Scholar
  • 30 Lin W, Jin Y, Hu X. et al. AMPK/PGC-1α/GLUT4-mediated effect of icariin on hyperlipidemia-induced non-alcoholic fatty liver disease and lipid metabolism disorder in mice. Biochemistry (Mosc) 2021; 86: 1407-1417
    CrossrefPubMedGoogle Scholar
  • 31 JZ AL, Alshammari GM, AlFaris NA. et al. Ellagic acid protects against non-alcoholic fatty liver disease in streptozotocin-diabetic rats by activating AMPK. Pharm Biol 2022; 60: 25-37
    CrossrefPubMedGoogle Scholar
  • 32 Li L, Li Q, Huang W. et al. Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR pathway. Front Pharmacol 2021; 12: 589273
    CrossrefPubMedGoogle Scholar
  • 33 Zhang Y, Wen J, Liu D. et al. Demethylenetetrahydroberberine alleviates nonalcoholic fatty liver disease by inhibiting the NLRP3 inflammasome and oxidative stress in mice. Life Sci 2021; 281: 119778
    CrossrefPubMedGoogle Scholar
  • 34 Ruan S, Han C, Sheng Y. et al. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3. Int Immunopharmacol 2021; 100: 108126
    CrossrefPubMedGoogle Scholar